0001062993-24-001164.txt : 20240122
0001062993-24-001164.hdr.sgml : 20240122
20240122185920
ACCESSION NUMBER: 0001062993-24-001164
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240119
FILED AS OF DATE: 20240122
DATE AS OF CHANGE: 20240122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McWherter Charles
CENTRAL INDEX KEY: 0001588862
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36500
FILM NUMBER: 24550142
MAIL ADDRESS:
STREET 1: C/O CYMABAY THERAPEUTICS, INC.
STREET 2: 7575 GATEWAY BLVD., SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001042074
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 943103561
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-293-8800
MAIL ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX, INC.
DATE OF NAME CHANGE: 20090721
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX INC
DATE OF NAME CHANGE: 19970710
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-01-19
0001042074
CymaBay Therapeutics, Inc.
CBAY
0001588862
McWherter Charles
C/O CYMABAY THERAPEUTICS, INC.
7575 GATEWAY BLVD., SUITE 110
NEWARK
CA
94560
0
1
0
0
President of R&D
1
Common Stock
2024-01-19
4
M
0
2250
1.06
A
17250
D
Common Stock
2024-01-19
4
S
0
2250
23.6721
D
15000
D
Common Stock
2024-01-19
4
M
0
2778
1.72
A
17778
D
Common Stock
2024-01-19
4
S
0
2778
23.6641
D
15000
D
Common Stock
2024-01-19
4
M
0
1916
1.82
A
16916
D
Common Stock
2024-01-19
4
S
0
1916
23.6641
D
15000
D
Common Stock
2024-01-19
4
M
0
8334
10.00
A
23334
D
Common Stock
2024-01-19
4
S
0
8334
23.6760
D
15000
D
Common Stock
2024-01-19
4
M
0
3125
11.69
A
18125
D
Common Stock
2024-01-19
4
S
0
3125
23.6760
D
15000
D
Employee Stock Option (right to buy)
1.06
2024-01-19
4
M
0
2250
0
D
2026-01-25
Common Stock
2250
51750
D
Employee Stock Option (right to buy)
1.72
2024-01-19
4
M
0
2778
0
D
2027-01-18
Common Stock
2778
97222
D
Employee Stock Option (right to buy)
1.82
2024-01-19
4
M
0
1916
0
D
2026-07-24
Common Stock
1916
44084
D
Employee Stock Option (right to buy)
10.00
2024-01-19
4
M
0
8334
0
D
2025-01-06
Common Stock
8334
91666
D
Employee Stock Option (right to buy)
11.69
2024-01-19
4
M
0
3125
0
D
2028-01-23
Common Stock
3125
146875
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 29, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.48 to $24.20, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.45 to $24.305, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vested as to 1/4 of the underlying shares on the first anniversary of the grant date and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.
The option vested as to 1/2 of the underlying shares on December 30, 2016 and the remaining 1/2 of the underlying shares vested on January 4, 2017.
The option vested as to 1/4 of the underlying shares on January 1, 2019 and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.
/s/ Paul Quinlan, as attorney-in-fact for Charles McWherter
2024-01-22